[ad_1]
Geneva, Switzerland, March 14, 2024 – Addex Therapeutics (SIX: ADXN), a clinical-stage pharmaceutical company focused on drug discovery and development based on allosteric modulation, today announced that CEO Tim Dyer will attend Bio-Europe 2024, March 18-20 Spring Meeting, 2024 in Barcelona, Spain. Dr. Robert Lütjens, Head of Biological Discovery, will also attend the event.
Mr. Dyer will provide a company update and discuss Addex’s latest developments during his presentation.
Demo details:
Date: Tuesday, March 19, 2024
Time: 11:00 – 11:15 CET
Room: 133/134
Location: Barcelona International Convention Center
Mr. Dyer and Dr. Lütjens will participate in one-on-one sessions throughout the conference. For more information or to schedule a one-on-one meeting, please contact IR@addexpharma.com through the conference online collaboration system.
About Addex Therapy
Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of novel oral small molecule drugs known as allosteric modulators of neurological diseases. Allosteric modulators offer several potential advantages over traditional non-allosteric molecules and could provide improved therapeutic approaches to traditional “orthosteric” small molecules or biologic drugs. Addex’s allosteric modulator drug discovery platform targets receptors and other proteins considered critical for therapeutic intervention. Addex’s lead drug candidate, ADX71149 (mGlu2 positive allosteric modulator, or PAM), was developed in collaboration with Janssen Pharmaceuticals, Inc. and is currently in Phase 2 clinical trials for the treatment of epilepsy. The company’s second clinical program, dipraglurant (mGlu5 negative allosteric modulator, or NAM), is being evaluated for future development in post-stroke recovery. Indivior PLC has licensed Addex’s GABAB PAM program for the development of drug candidates focused on substance use disorders. Addex is also advancing an extensive preclinical pipeline that includes development of a series of GABAB PAMs for chronic cough, mGlu7 NAMs for stress-related disorders, M4 PAMs for schizophrenia and other forms of psychosis, and M4 PAMs for mild mGlu2 NAMs in neurocognitive disorders and depression. Addex’s shares are listed on SIX Swiss Exchange and the American depositary shares representing its shares are listed on the Nasdaq Capital Market and trade on each exchange under the ticker “ADXN”.
contact method:
forward-looking statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding the anticipated use of proceeds from this offering. Words such as “may”, “will”, “could”, “would”, “should”, “expect”, “plan”, “anticipate”, “intend”, “believe”, “estimate”, “predict” etc. The words “project,” “potential,” “continue,” “goal” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that could cause actual events or results to differ from any Results expressed or implied by forward-looking statements may differ materially. Please be aware of statements contained in this release, including, but not limited to, uncertainties related to market conditions. These and other risks and uncertainties are described in more detail in the section titled “Risk Factors” in Addex Therapeutics’ Annual Report on Form 20-F for the year ended December 31, 2022, filed with the SEC on March 30, 2023 .Final prospectus supplement and accompanying prospectus and other documents that Addex Therapeutics may file with the SEC in the future. Any forward-looking statements contained in this press release represent Addex Therapeutics’ views only as of the date of this press release and should not be relied upon as representing its views as of any subsequent date. Addex Therapeutics expressly disclaims any obligation to update any forward-looking statements.
[ad_2]
Source link